Mymetics Starts Research Collaboration Project in Cancer Immunotherapy with eTheRNA

Author's Avatar
Apr 12, 2019
Article's Main Image

EPALINGES, SWITZERLAND / ACCESSWIRE / October 16, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines, announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project with eTheRNA immunotherapy NV, a clinical stage biotech company developing novel mRNA cancer immunotherapies.